ProMIS Neurosciences Inc. (PMN) — SEC Filings

Latest SEC filings for ProMIS Neurosciences Inc. (PMN), explained in plain English.

Sentiment Overview: 1 bullish, 5 bearish, 43 neutral, 1 mixed

Recent Filings (50)

• ARS Filing — ARS · 2026-04-09T16:03:10-04:00 [neutral]
• ProMIS Neurosciences Files Proxy Materials — DEFA14A · 2026-04-09T16:02:22-04:00 [neutral] Risk: low
  ProMIS Neurosciences Inc. filed a DEFA14A on April 9, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents a
• ProMIS Neurosciences Filing Effectiveness Noted — EFFECT · 2026-04-03T00:15:25-04:00 [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an EFFECT form on April 3, 2026, indicating the effectiveness of a filing related to their securities. The filing, with SEC Acce
• EFFECT Filing — EFFECT · 2026-03-27T00:15:28-04:00 [neutral]
• ProMIS Neurosciences Files S-3 for Future Securities Offerings — S-3 · 2026-03-25T17:22:52-04:00 [neutral]
  ProMIS Neurosciences Inc. filed an S-3 registration statement on March 25, 2026, which allows the company to raise money by selling various types of securities,
• ProMIS Neurosciences Pushes PMN310 Amidst Funding Needs — 10-K · 2026-03-25T16:34:05-04:00 [bearish] Risk: high
  ProMIS Neurosciences Inc. (PMN) reported no revenue from product sales for the fiscal year ended December 31, 2025, continuing a trend of losses since inception
• ProMIS Neurosciences Files 8-K on Financial Results — 8-K · 2026-03-25T08:06:09-04:00 [neutral]
  ProMIS Neurosciences Inc. filed an 8-K on March 25, 2026, reporting its results of operations and financial condition under Item 2.02. This filing, with accessi
• ProMIS Neurosciences Inc. Files 8-K — 8-K · 2025-12-16T00:00:00.000Z [neutral] Risk: low
  On December 12, 2025, ProMIS Neurosciences Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at Suite 20
• ProMIS Neurosciences Files 8-K — 8-K · 2025-11-24T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on November 24, 2025, reporting amendments to its articles of incorporation or bylaws, other events, and financial statem
• ProMIS Neurosciences Files 8-K on Shareholder Vote Matters — 8-K · 2025-11-19T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed an 8-K on November 17, 2025, reporting on a submission of matters to a vote of security holders. The company, formerly known as
• ProMIS Neurosciences R&D Soars, Net Loss Widens to $29M — 10-Q · 2025-11-12T00:00:00.000Z [bearish] Risk: high
  ProMIS Neurosciences Inc. reported a significant net loss of $29,045,059 for the nine months ended September 30, 2025, a stark contrast to the net income of $3,
• ProMIS Neurosciences Announces Board and Officer Changes — 8-K · 2025-10-24T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. announced on October 22, 2025, a change in its board of directors, including the election of new directors and the appointment of cert
• ProMIS Neurosciences Seeks Shareholder Nod for 1:5 to 1:25 Reverse Split — DEF 14A · 2025-10-03T00:00:00.000Z [mixed] Risk: medium
  ProMIS Neurosciences Inc. (PMN) is holding a Special Meeting on November 17, 2025, to seek shareholder approval for a share consolidation (reverse stock split)
• ProMIS Neurosciences Announces Board and Executive Changes — 8-K · 2025-09-30T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. announced on September 26, 2025, a change in its board of directors and executive compensation arrangements. The filing details the de
• ProMIS Neurosciences Files 8-K — 8-K · 2025-09-03T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on September 3, 2025, reporting on various events. The filing includes information related to financial statements and ex
• ProMIS Neurosciences Enters Material Definitive Agreement — 8-K · 2025-08-19T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. entered into a material definitive agreement on August 13, 2025. The company, formerly known as Amorfix Life Sciences Ltd., is incorpo
• ProMIS Neurosciences' Losses Mount Amid Soaring R&D Costs — 10-Q · 2025-08-13T00:00:00.000Z [bearish] Risk: high
  ProMIS Neurosciences Inc. (PMN) reported a significant increase in net loss for the three and six months ended June 30, 2025, reaching $10.1 million and $17.5 m
• ProMIS Neurosciences Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-07-28T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. announced on July 28, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of e
• ProMIS Neurosciences Enters Material Definitive Agreement — 8-K · 2025-07-22T00:00:00.000Z [neutral] Risk: medium
  On July 21, 2025, ProMIS Neurosciences Inc. entered into a material definitive agreement. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is incorpora
• Sun Pharma to Acquire ProMIS Neurosciences for $117M — 8-K · 2025-07-07T00:00:00.000Z [bullish] Risk: medium
  ProMIS Neurosciences Inc. announced on July 3, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Sun Pharmaceutical Indust
• ProMIS Neurosciences Files 8-K on Board Changes and Votes — 8-K · 2025-06-13T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed an 8-K on June 13, 2025, reporting on events from June 12, 2025. The filing covers the departure and election of directors, appo
• ProMIS Neurosciences Files Q1 2025 10-Q — 10-Q · 2025-05-12T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as AMORFIX LIFE SCIENCES LTD, reported financial data
• ProMIS Neurosciences Files 2025 Proxy Statement — DEF 14A · 2025-04-29T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting on June 12, 2025. The company, formerly known as Amorfi
• ProMIS Neurosciences Files 2024 Annual Report — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as AMORFIX LIFE SCIENCES LTD, is based in Tor
• ProMIS Neurosciences Files 8-K — 8-K · 2025-02-25T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on February 25, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerl
• ProMIS Neurosciences Announces Board and Executive Changes — 8-K · 2025-02-19T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. announced on February 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• ProMIS Neurosciences Files 8-K — 8-K · 2025-01-27T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on January 27, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• ProMIS Neurosciences Files 8-K — 8-K · 2025-01-10T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on January 10, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, o
• ProMIS Neurosciences Faces Delisting Concerns — 8-K · 2025-01-08T00:00:00.000Z [bearish] Risk: high
  ProMIS Neurosciences Inc. filed an 8-K on January 8, 2025, to report a notice of delisting or failure to meet continued listing standards. The company, formerly
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• ProMIS Neurosciences Q3 2024 Financials Revealed — 10-Q · 2024-11-14T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $32,689,190 and total liabilities of $18
• SC 13G/A Filing — SC 13G/A · 2024-11-06T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-05T00:00:00.000Z [neutral]
• ProMIS Neurosciences Files 8-K on Shareholder Vote Matters — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed an 8-K on October 24, 2024, reporting on matters submitted to a vote of security holders as of October 23, 2024. The filing deta
• SC 13G Filing — SC 13G · 2024-10-16T00:00:00.000Z [neutral]
• ProMIS Neurosciences Announces Board and Officer Changes — 8-K · 2024-10-10T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. announced on October 8, 2024, changes in its board of directors and executive officers. The filing details the election of new directo
• ProMIS Neurosciences Files Proxy Statement for Oct. 23 Meeting — DEF 14A · 2024-09-09T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. filed a definitive proxy statement (DEF 14A) on September 9, 2024, for its annual meeting on October 23, 2024. The company, formerly k
• ProMIS Neurosciences Q2 2024 Update: Cash Stable, Warrant Data Detailed — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $18.96 million as of June 30, 20
• SC 13G Filing — SC 13G · 2024-08-05T00:00:00.000Z [neutral]
• ProMIS Neurosciences Completes Merger with HealthBank Global — 8-K · 2024-07-29T00:00:00.000Z [neutral] Risk: medium
  On July 22, 2024, ProMIS Neurosciences Inc. announced the closing of its previously disclosed business combination with HealthBank Global Holdings Inc. The comb
• ProMIS Neurosciences Files 8-K Report — 8-K · 2024-07-26T00:00:00.000Z [neutral] Risk: low
  On July 26, 2024, ProMIS Neurosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a
• ProMIS Neurosciences Faces Nasdaq Delisting Warning — 8-K · 2024-07-05T00:00:00.000Z [bearish] Risk: high
  ProMIS Neurosciences Inc. announced on July 2, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The co
• ProMIS Neurosciences Holds Shareholder Meeting — 8-K · 2024-06-14T00:00:00.000Z [neutral] Risk: low
  On June 13, 2024, ProMIS Neurosciences Inc. filed an 8-K report to announce the results of its annual and special meeting of shareholders. The company's shareho
• ProMIS Neurosciences Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-14T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. (PMN) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. ProMIS Neurosciences Inc. filed a 10-Q for the period ending March
• ProMIS Neurosciences Files 8-K Report — 8-K · 2024-04-30T00:00:00.000Z [neutral] Risk: low
  On April 30, 2024, ProMIS Neurosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD di
• ProMIS Neurosciences Inc. Announces 2024 Annual Meeting of Shareholders — DEF 14A · 2024-04-25T00:00:00.000Z [neutral] Risk: low
  ProMIS Neurosciences Inc. (PMN) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Shareholders for ProMIS Neuroscienc
• ProMIS Neurosciences Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-04-01T00:00:00.000Z [neutral] Risk: medium
  ProMIS Neurosciences Inc. (PMN) filed a Annual Report (10-K) with the SEC on April 1, 2024. ProMIS Neurosciences Inc. filed its 2023 Form 10-K on April 1, 2024.
• Sphera Funds Mgmt Amends ProMIS Neurosciences Stake — SC 13G/A · 2024-02-05T00:00:00.000Z [neutral]
  Sphera Funds Management Ltd., an Israeli investment firm, has filed an amended SC 13G/A, indicating a change in their beneficial ownership of ProMIS Neuroscienc
• ProMIS Neurosciences Enters Material Definitive Agreement — 8-K · 2024-01-05T00:00:00.000Z [neutral]
  ProMIS Neurosciences Inc. filed an 8-K on January 5, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates a significant new co
• ProMIS Neurosciences Files 8-K on Corporate Governance, Compensation — 8-K · 2024-01-03T00:00:00.000Z [neutral]
  ProMIS Neurosciences Inc. filed an 8-K on January 3, 2024, reporting events that occurred on December 30, 2023. This filing primarily covers routine corporate g